• HOME>
  • Investor Relations
Japanese
  • IR News
  • News Releases
  • Oct. 03, 2022 (PDF/601KB)Corporate
    Sumitomo Pharma and Sumitovant Biopharma Announce Offer to Acquire Outstanding Shares of Myovant Sciences
  • Sep. 30, 2022 (PDF/407KB)Licensing
    Sumitomo Pharma and MELTIN Enter into Marketing Alliance for MELTz Hand Rehabilitation System and Launch It
  • Sep. 29, 2022 (PDF/160KB)R&D
    Joint Research between The Kitasato Institute and Sumitomo Pharma: Drug Combination of Meropenem and KSP-1007 for Treatment of Carbapenem- Resistant Bacteria Infections Designated as Qualified Infectious Disease Product (QIDP)/Fast Track
  • Sep. 27, 2022 (PDF/183KB)Corporate
    Appeal of Inter Partes Review (IPR) USPTO Decision on the Method of Use Patent for LATUDA
  • Sep. 13, 2022Others
    Posted Integrated Report 2022
  • Oct. 03, 2022 (PDF/601KB)Corporate
    Sumitomo Pharma and Sumitovant Biopharma Announce Offer to Acquire Outstanding Shares of Myovant Sciences
  • Sep. 30, 2022 (PDF/407KB)Licensing
    Sumitomo Pharma and MELTIN Enter into Marketing Alliance for MELTz Hand Rehabilitation System and Launch It
  • Sep. 29, 2022 (PDF/160KB)R&D
    Joint Research between The Kitasato Institute and Sumitomo Pharma: Drug Combination of Meropenem and KSP-1007 for Treatment of Carbapenem- Resistant Bacteria Infections Designated as Qualified Infectious Disease Product (QIDP)/Fast Track
  • Sep. 27, 2022 (PDF/183KB)Corporate
    Appeal of Inter Partes Review (IPR) USPTO Decision on the Method of Use Patent for LATUDA
  • Sep. 02, 2022 (PDF/585KB)Corporate
    Sumitomo Pharma Announces Personnel Changes

IR Calendar

  • Oct. 31, 2022
    2nd Quarter of FY2022 financial results announcement
    (planned, 3:30 p.m. )
  • Nov. 01, 2022
    Analysts meeting of 2nd
    Quarter financial results FY2022

more

  • WITH GRADE AAA Corporate Websites 2020 Nikko Investor Relations Co.,Ltd. Ranking in all listed companies in Japan

  • Internet IR Commendation Award2021

  • Internet IR sustainable Award2021